Van Der Laan, L.Hudson, M.McPherson, S.Zondervan, P.Thomas, R.Kwekkeboom, J.Lindsay, A.Burt, A.Kazemier, G.Tilanus, H.Bassendine, M.Metselaar, H.2014-06-102014-06-102010Transplantation Proceedings, 2010; 42(10):4573-45770041-13451873-2623http://hdl.handle.net/2440/83310A 2-center retrospective analysis was performed in 60 patients undergoing liver transplantation for hepatitis C virus (HCV)–related disease (cyclosporine in 20, tacrolimus in 40). Mean (±SEM) follow-up was 23.6 ± 22.5 and 22.3 ± 13.7 months in patients receiving cyclosporine or tacrolimus, respectively. Clinically indicated biopsies were performed in 15/20 cyclosporine patients (75%) and 22/40 tacrolimus patients (55%; P = .17). The Ishak fibrosis score was significantly lower in cyclosporine-treated patients versus tacrolimus-treated patients (mean 1.7 ± 0.4 vs 3.1 ± 0.4; P = .023), as was percentage of fibrosis grade Ishak ≥4 (7% vs 41%; P = .028). The mean time to moderate fibrosis (Ishak score ≥3) was 38.2 ± 15.1 months in cyclosporine patients (4/15) and 23.5 ± 12.6 months in tacrolimus patients (14/22); the difference was not statistically significant (P = .09). This retrospective study suggests that cyclosporine-based immunosuppression is associated with less severe hepatic fibrosis in HCV-positive liver transplant recipients compared with tacrolimus-based regimens, but a larger prospective comparative trial is necessary to confirm these findings.en© 2010 by Elsevier Inc. All rights reserved.HumansHepatitis CLiver CirrhosisDisease ProgressionTacrolimusCyclosporineImmunosuppressive AgentsLiver TransplantationRetrospective StudiesMiddle AgedFemaleMaleJournal article002013053910.1016/j.transproceed.2010.10.0130002857322001572-s2.0-7865044024618796Burt, A. [0000-0002-3011-7774]